In short
Redasemtide, also known as S-005151, is an investigational drug currently being studied in clinical trials for the treatment of acute ischemic stroke. This article explores the ongoing phase 2b clinical trial that aims to evaluate the efficacy and safety of Redasemtide in adult patients who are not eligible for standard treatments like tissue plasminogen activator (tPA) or thrombectomy. The trial focuses on patients with supratentorial ischemic stroke and compares Redasemtide to a placebo in a randomized, double-blind study.
At a glance
- Drug Name
- Redasemtide (S-005151)
- Study Type
- Phase 2b, multinational, randomized, double-blind
- Condition
- Acute Ischemic Stroke
- Participant Criteria
- Adults ≥18 years, supratentorial ischemic stroke, NIHSS score 8-22, not eligible for tPA or thrombectomy
- Treatment
- IV infusion once daily for 5 consecutive days (0.75 mg/kg or 1.5 mg/kg)
- Primary Endpoint
- Modified Rankin Scale (mRS) score at Day 90
- Secondary Endpoints
- Functional independence, neurological improvement, quality of life measures
- Study Duration
- 6 months (5-day treatment + 180-day follow-up)
- Safety Monitoring
- Adverse events, lab tests, vital signs, ECGs, and suicide risk assessment
What is Redasemtide?
Redasemtide, also known as S-005151, is a new medication being studied for the treatment of acute ischemic stroke. An acute ischemic stroke occurs when blood flow to part of the brain is blocked, usually by a blood clot, leading to damage of brain tissue. Redasemtide is currently undergoing clinical trials to assess its effectiveness and safety in treating this serious condition.
How Redasemtide Works
While the exact mechanism of action is not fully described in the provided information, Redasemtide is being investigated as a potential treatment for patients who are not eligible for standard stroke treatments. These standard treatments typically include:
- Tissue plasminogen activator (tPA): A medication that helps dissolve blood clots
- Thrombectomy: A surgical procedure to remove blood clots from blood vessels in the brain
Redasemtide is administered as an intravenous (IV) infusion, which means it's given directly into the bloodstream through a vein. This method allows the medication to reach the affected areas of the brain quickly.
Clinical Trial Details
A Phase 2b clinical trial is currently underway to further investigate the efficacy and safety of Redasemtide. Here are some key details about the study:
- It's a multinational, randomized, double-blind study, which means participants are randomly assigned to different treatment groups, and neither the participants nor the researchers know who is receiving which treatment.
- The study compares two different doses of Redasemtide (0.75 mg/kg and 1.5 mg/kg) to a placebo (a substance with no active medication).
- The medication is given once daily for 5 consecutive days during hospitalization.
- The study follows participants for 180 days after treatment, with check-ups at 30, 90, and 180 days.
Eligibility Criteria
Not everyone with an acute ischemic stroke is eligible for this study. Some key eligibility criteria include:
- Adults aged 18 years or older
- Diagnosed with a specific type of ischemic stroke (supratentorial)
- Able to start treatment within 25 hours of stroke onset
- Not eligible for standard treatments like tPA or thrombectomy
- Have a certain level of stroke severity, as measured by a standardized scale (NIHSS score of 8 to 22)
- Medically stable except for the stroke and its complications
Potential Benefits
The main goal of this study is to see if Redasemtide can improve outcomes for stroke patients. Researchers are looking at several measures to determine if the medication is effective, including:
- Improvement in physical function and disability (measured by scales like the modified Rankin Scale or mRS)
- Improvement in daily living activities (measured by the Barthel Index or BI)
- Reduction in stroke severity (measured by the National Institutes of Health Stroke Scale or NIHSS)
- Improvement in quality of life
Safety and Side Effects
An earlier Phase 2 study of Redasemtide showed promising results:
- The medication was well-tolerated by patients.
- The number of side effects (called treatment-emergent adverse events or TEAEs) was similar between the Redasemtide group and the placebo group.
- There were no notable differences in the types of side effects between the groups.
However, it's important to note that this is still an investigational medication, and more research is needed to fully understand its safety profile and potential side effects.
In conclusion, Redasemtide represents a potential new treatment option for patients with acute ischemic stroke who are not eligible for current standard treatments. While the results so far are encouraging, it's important to remember that this medication is still in the testing phase. Patients interested in learning more about Redasemtide or the ongoing clinical trial should consult with their healthcare providers.